Tumor growth is an evolutionary process governed by somatic mutation, clonal selection and random genetic drift, constrained by the co-evolution of the microenvironment 1,2 . Tumor subclones are subpopulations of tumor cells with a common set of mutations resulting from the expansion of a single cell during tumor development, and have been observed in a significant fraction of cancers and across multiple cancer types 3 .
Tumor growth is an evolutionary process governed by somatic mutation, clonal selection and random genetic drift, constrained by the co-evolution of the microenvironment 1, 2 . Tumor subclones are subpopulations of tumor cells with a common set of mutations resulting from the expansion of a single cell during tumor development, and have been observed in a significant fraction of cancers and across multiple cancer types 3 .
Peter Nowell proposed that tumors evolve through sequential genetic events 4 , whereby one cell acquires a selective advantage so that its lineage becomes predominant. According to this traditional model, the selective advantage is conferred by a small set of driver mutations, but, as the subclones that bear them expand successively, they accumulate passenger mutations as well, which can be detected in sequencing experiments 1 . Genomes of individual tumors contain hundreds to many thousands of these genetic variants, at a wide range of frequencies 5, 6 . Given that genetic drift alone can drive novel variants to high frequencies, it is of great interest to discern the relative importance of selection and drift in shaping the frequency distribution of variants in any given tumor.
Williams et al. 7 recently proposed a way to do so. They found that a simple model of tumor growth in which all novel variants are selectively neutral, that is, whose dynamics are governed entirely by drift, predicts a linear relationship between the number of mutations More recently, multiple myelomas with evidence for the proposed linear relationship were associated with poorer prognosis 8 .
While providing an interesting approach to infer selection in human cancers, unfortunately four major simplifying assumptions underlie the analysis by Williams et al. that might render the conclusions questionable.
First, inferring f of variants from their VAF requires accurate estimates of local copy number, overall tumor purity and ploidy. Williams et al. attempted to account for some of these factors by restricting their analyses to variants with VAF between 0.12 and 0.24 and located in copy-neutral regions of the genome. However, even in that limited VAF window, the VAF of a mutation does not reflect its true f in many cases. For example, in tumors with whole genome duplications, i.e. 37% of tumors in the analyzed dataset 9 , the peak of clonal mutations acquired after the whole genome doubling event is at or below VAF = 0.25 (one out of four copies in a 100% pure tumor sample), which would lead to artificial deviation from the linear fit within that VAF window.
Second, the interpretation of the analyses is inconsistent with the use of neutrality as a null model. is neither a necessary nor a sufficient property of neutrally evolving tumors (Fig. 1b) . Although it can be shown that the expected cumulative number of mutations -i.e. the average over many independent samples -∝ ! ! , 10 due to the biological noise modeled in branching processes, a typical realization of the neutral process in a single sample deviates substantially from the expected linear fit, rendering an R-squared threshold inaccurate to infer neutrality. As a result, discrimination of neutral and non-neutral simulated tumors using a linear fit is almost arbitrary, with 53.5% false positive neutral calls in non-neutral tumors (Fig. 1b) and an area under the ROC curve of 0.42 for the classification of 1,919 neutral and 1,919 non-neutral tumors (Fig. 1c) . http://cancergenome.nih.gov/.
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Simulations -continuous deterministic models
The deterministic equations described in Williams et al. 1 relate the number of cells in a tissue growing exponentially, N,
and the cumulative number of mutations, M:
at any given time t ≥ 0, where λ > 0 is the division rate per unit of time, β ≥ 0 is the unitless "effective" division fraction, i.e. the fraction of divisions in which both daughter cells survive (β = 1 for no cell death, β < 1 to model cell death), and µ > 0 is the mutation rate per cell division.
We have used these continuous deterministic models to simulate tumor growth in silico and followed each mutation and its corresponding variant cell fraction. To derive the cell fractions, we follow the progeny of the mother cell within which each mutation occurred. 
where the second term is omitted when t < t 2 . Similarly, the number of cells at time t from the subclonal lineage (i.e. with parameters β 2 , λ 2 , µ 2 ) is
when t > t 2 and N 2 (t) = 0 otherwise. The total cell count at time t is
The tumor growth simulation is terminated at time T > t 2 and we derive the distribution at time T of the cell fractions for all mutations in the tumor.
Following the number of mutations and their cell fraction
Because the equations are continuous, they can lead to non-integer numbers of mutations and cell divisions. Hence, rather than deriving the number of mutations and their allele frequencies f at discrete time points, we model divisions in continuous time. We assess the number of additional mutations that have been added in fixed (small) time intervals of length dt. From Eq. (1), we find that the number of additional mutations occurring in the time interval [t, t + dt] within a population of cells from the same lineage (i.e. parameters β, division rate λ, and mutation rate µ) is:
For a mutation occurring at time t, we may compute the variant cell fraction at time T. If the mutation occurred in a cell from the MRCA lineage that was not inherited by the subclone-initiating cell, then the variant cell fraction is
If the mutation occurred in the subclone, then the variant cell fraction is
Finally, if the mutation occurred in an ancestor cell of the subclone-initiating cell, then the variant cell fraction is
Alternatively, we may calculate variant cell fractions in two steps, first determining the variant cell fraction of a mutation within the subpopulation of cells from the same lineage, and then scaling the variant cell fraction by the size of that subpopulation relative to the total cell population.
Setting the parameters for the grid of simulations
In each of our simulations the subclone growing under selective advantage appears at the 11 th generation and the tumor is sampled at the 40th generation with a virtual purity of 100%. The number of initial clonal mutations µ 0 is not part of these models, and we arbitrarily set µ 0 = µ 2 . We fix the following parameters: clonal 
Simulations -fully stochastic models
To model stochastic discrete tumor growth, we use branching processes with the Gillespie algorithm 2 . These simulated tumors grow under asynchronous division, with zero or one subclone.
This was coded in Java. Each cell is a Java object and has four attributes: a Boolean value reporting whether the cell is alive or dead; an integer for the average number of mutations per division; an integer with mother cell ID; and an ArrayList of all MutationSets inherited from the mother cell. MutationSet is another class, for which each object contains one integer for the mother cell ID and one integer for the number of mutations within them. The constructor of MutationSet takes the mutation rate of the mother cell as average number of events per interval of a Poisson distribution to draw the number of mutations.
Starting with an ArrayList of one tumor initiating cell, for each of 2 20 cell division events, one cell is picked randomly from the living cells and either dies with probability P(cell death) or divides into two daughter cells with probability P(division) = 1 -P(cell death), akin to the Gillespie algorithm.
In our simulations, the subclone appears at the 2 8 th division (~8 th generation)
by changing the division rate value of one of the cells, and the tumor is sampled at the The subclone is selected for division with probability With higher P(cell death), the first divisions are more likely to lead to the death of all cells and the tumor quickly stops growing. To limit this effect when cell death is high, we force the D first divisions to happen, i.e. P(cell death) = 0 transiently until at least 2D cells are alive.
Setting the parameters for the grid simulations
In our simulations, starting from one tumor initiating cell, for each of the 2 20 cell division events, one cell is picked randomly and either dies with probability P(cell death) = 0.2 or divides into two daughter cells with probability P(division) = 1 -P(cell death) = 0.8. The subclone appears at the 2 8 th division (~8 th generation) and the tumor is sampled at the 2 20 -th division (~20 th generation). The ancestor clone's mutation rate µ ~ Pois (16) . The average depth of coverage is 100X (see section on simulating tumor variant allele frequencies from sequencing data). In our simulations,
We explore a grid of values for 
Simulating tumor variant allele frequencies from sequencing data
Using the tumor growth models presented here, we can derive the exact number of mutations and their prevalence within a virtual tumor. These are taken as input to simulate the frequencies that would be observed in the sequencing reads from real tumor tissue.
In order to test the initial hypothesis, i.e. 
Calling neutral tumors
We followed the description by Williams et al. 1 to call neutral and non-neutral tumors based on the variant allele frequencies of their somatic single nucleotide variants. Tumors with less than 12 mutations with 0.12 ≤ VAF ≤ 0.24 were removed.
From the TCGA dataset, only tumors with a purity of at least 70%, as inferred by ASCAT 3 , were analyzed.
We calculated the explained variance (R 2 ) for linear regression models both with fixed intercept (intercept = 0) and without fixing the intercept, using the R . Results presented in the manuscript were obtained using a variable intercept. In Supplementary Fig. 1, we show the heat map of Figure 1a using a fixed intercept. Both methods show 97.5% agreement (Supplementary Fig. 2 ). 
Detection of selection in neutral and non-neutral tumors -dN/dS Dataset
We ran our analyses on the data from The Cancer Genome Atlas, using 
Grouping variants into clonal and subclonal categories
To classify variants as clonal or subclonal, we used a one-sided proportion test to assess whether the alternate and total read counts of each variant were compatible with its clonality, given its underlying number of DNA copies, and the overall tumor purity. This method is previously described in Alexandrov et al.
dN/dS analysis and control gene sets
We performed dN/dS analysis to detect positive or negative selection of nonsynonymous variants, as described by Martincorena et al. 6 The R package dNdScv was used to derive the dN/dS values and is available on github:
https://github.com/im3sanger/dndscv. We ran dN/dS separately on clonal and 9 subclonal mutations and separately in the neutral and non-neutral tumors, using a FAT1, FAT4, FBXO11, FBXW7, FGFR1, FGFR2, FGFR3, FLT3, FOXA1, FOXL2, FUBP1 , GATA1, GATA2, GATA3,  GNA11, GNAQ, GNAS, GRIN2A, H3F3A, H3F3B, HIF1A, HIST1H3B, HNF1A, HRAS, IDH1, IDH2, IKBKB, IKZF1, IL6ST,  IL7R, JAK1, JAK2, JAK3, KCNJ5, KDM5C, KDM6A, KDR, KIT, KLF4, KMT2C, KMT2D, KRAS, MAP2K1, MAP2K2,  MAP2K4, MAX, MED12, MEN1, MET, MLH1, MPL, MSH2, MSH6, MTOR, MYD88, MYOD1, NF1, NF2, NFE2L2, NFKBIE,  NOTCH1, NOTCH2, NPM1, NRAS, NT5C2, NTRK3, PAX5, PBRM1, PDGFRA, PHF6, PHOX2B, PIK3CA, PIK3R1, PLCG1,  POLE, POT1, PPP2R1A, PPP6C, PRDM1, PRKACA, PRKAR1A, PTCH1, PTEN, PTPN11, PTPN13, PTPRB, RAC1, RAD21,  RB1, RET, RHOA, RNF43, RPL10, RPL5, RUNX1, SETBP1, SETD2, SF3B1, SH2B3, SMAD4, SMARCA4, SMARCB1, SMO,  SOCS1, SPEN, SPOP, SRC, SRSF2, STAG2, STAT3, STAT5B, STK11, SUFU, TBL1XR1, TBX3, TERT, TET2, TNFAIP3,  TNFRSF14, TP53, TRAF7, TSC1, TSC2, TSHR, U2AF1, UBR5, USP8, VHL, WT1, XPO1, ZRSR2. co-expressed with g, and N i is the number of co-expressed genes with gene i. We ran dN/dS again on 100 of these 192-gene sets and found that 4 and 5 out of 100 gene lists yielded 95% confidence intervals of dN/dS >1 for subclonal mutations in neutral and non-neutral tumours, respectively.
Effect of copy number
We repeated the analyses after selecting only variants that fall within diploid regions, i.e. 1 copy of allele A and 1 copy of allele B according to ASCAT 3 , to show that the results were not induced by unreliable neutral calls, which could have resulted from the distortion of allele frequencies by copy number changes (Supplementary 
